EGFR and breast carcinoma: Although we did not find clinical mutation of TMEM25 affecting its checkpoint function on monomeric-EGFR/STAT3 signaling in breast cancer, we found quite a few clinical mutations of TMEM25 resulting in a loss of this checkpoint function in other types of cancer including colorectal cancer.